AM-928 / AcadeMab - LARVOL DELTA

Safety of AM-928 Infusion in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: AcadeMab Biomedical Inc. | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

First-in-human • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Safety of AM-928 Infusion in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: AcadeMab Biomedical Inc. | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial primary completion date • Oncology • Solid Tumor

Safety of AM-928 Infusion in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: AcadeMab Biomedical Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

AM-928, a new antibody drug developed by the US FDA, will start Phase I clinical trials for advanced solid cancer [Google translation] (udn.com) - "The biotechnology start-up company Yansheng Biomedical announced...that the new antibody drug AM-928 has obtained the New Drug Clinical Trial (IND) approval from the US Food and Drug Administration (FDA), and will conduct the first phase for patients with advanced solid cancers."

IND • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Adenocarcinoma • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Safety of AM-928 Infusion in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: AcadeMab Biomedical Inc.

Metastases • New P1 trial • Oncology • Solid Tumor